Vanda Pharmaceuticals Inc. $VNDA Shares Sold by Goldman Sachs Group Inc.

Key Points

• Goldman Sachs Group Inc. has reduced its holdings in Vanda Pharmaceuticals by 11.9%, now owning approximately 693,852 shares, valued at $3.19 million.
• Vanda Pharmaceuticals reported a loss of ($0.46) EPS for the last quarter, missing analyst expectations and setting its FY 2025 guidance at -1.12 EPS.
• Equities analysts have mixed ratings on Vanda Pharmaceuticals, with one firm downgrading it from "hold" to "strong sell" while another maintains a "buy" rating with a target price of $20.00.

Goldman Sachs Group Inc. cut its holdings in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 11.9% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 693,852 shares of the biopharmaceutical company's stock after selling 93,965 shares during the quarter. Goldman Sachs Group Inc. owned about 1.18% of Vanda Pharmaceuticals worth $3,185,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of VNDA. Millennium Management LLC grew its holdings in shares of Vanda Pharmaceuticals by 220.0% during the 1st quarter. Millennium Management LLC now owns 2,139,591 shares of the biopharmaceutical company's stock worth $9,821,000 after purchasing an additional 1,470,898 shares during the period. Nuveen LLC purchased a new position in Vanda Pharmaceuticals during the 1st quarter valued at about $2,022,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Vanda Pharmaceuticals during the 1st quarter valued at about $875,000. GSA Capital Partners LLP boosted its holdings in Vanda Pharmaceuticals by 88.0% during the 1st quarter. GSA Capital Partners LLP now owns 260,215 shares of the biopharmaceutical company's stock valued at $1,194,000 after acquiring an additional 121,797 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Vanda Pharmaceuticals by 13.5% during the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 929,644 shares of the biopharmaceutical company's stock valued at $4,267,000 after acquiring an additional 110,262 shares during the period. 88.14% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on VNDA shares. Wall Street Zen cut Vanda Pharmaceuticals from a "hold" rating to a "strong sell" rating in a report on Saturday, August 2nd. HC Wainwright restated a "buy" rating and set a $20.00 target price on shares of Vanda Pharmaceuticals in a report on Thursday, August 21st. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Strong Buy" and an average target price of $16.50.

Vanda Pharmaceuticals Stock Up 1.4%

VNDA traded up $0.07 during trading on Tuesday, hitting $4.82. 61,008 shares of the stock were exchanged, compared to its average volume of 543,988. The firm has a market capitalization of $284.52 million, a P/E ratio of -4.26 and a beta of 0.74. Vanda Pharmaceuticals Inc. has a 1-year low of $3.81 and a 1-year high of $5.55. The stock has a fifty day moving average price of $4.55 and a two-hundred day moving average price of $4.52.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.12). The firm had revenue of $52.59 million for the quarter, compared to analyst estimates of $54.77 million. Vanda Pharmaceuticals had a negative return on equity of 12.89% and a negative net margin of 32.90%. Vanda Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts predict that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current year.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.